- The new business segment Transferra Nanosciences showcases its portfolio of liposomal drug delivery systems
- RESOMER® bioresorbable polymers celebrates their 30th anniversary
- Launch of new SOVIDINE™ brand for Chlorhexidine portfolio
Evonik will present the products and services of its new business segment Transferra Nanosciences, a leading provider of liposomal drug delivery systems, for the first time at CPhI this year (Barcelona, October 4 - 6). The Evonik booth C50 will be located in Hall 2. "The portfolio and expertise of Transferra Nanosciences, combined with Evonik’s competencies in polymer-based controlled release injectables, positions Evonik as a partner of choice for the development and manufacturing of a broad range of injectable drug products based, for example, on nucleotides or cytostatic compounds," explains Dr. Thomas Riermeier, Head of the Product Line Pharma Polymers & Services.
The other event to celebrate is the 30th anniversary of RESOMER®, a portfolio of biodegradable pharmaceutical polymers considered as the world standard in controlled release injectable and medical device applications. In honor of the 30th anniversary of the brand, Evonik just launched a campaign entitled RESOMER® - 30 years of empowering innovation. The initiative and its key visuals will be presented at CPhl in Barcelona.
Evonik will also present SOVIDINE™, the new brand of its chlorhexidine offering used in the pharmaceutical industry to manufacture antiseptics and disinfectants. "The brand stands for our commitment to international GMP (Good Manufacturing Practice) quality standards and to superior customer service," states Dr. Thomas Hermann, Head of Evonik’s Pharma & Food Ingredients Product Line.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around
€4.9 billion in 2015.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.